Lung cancer surfaces to be the predominant determinant of mortality worldwide constituting
13% and 19% of all new cancer cases and deaths related to cancer respectively. Molecular profiling
has now become a regular trend in lung cancer to identify the driver mutations. Epidermal
Growth Factor Receptor (EGFR) is the most regular driver mutation encountered in Non-Small Cell
Lung Cancer (NSCLC). Targeted therapies are now available for the treatment of EGFR mutant
NSCLC. EGFR mutation is more frequently expressed in adenocarcinoma than squamous cell carcinoma.
This article presents a detailed molecular insight of the therapeutic approaches for the treatment
of EGFR mutant lung cancer. The article delineates molecular mechanism of the drugs that are
approved, the drugs that are in clinical trial and the drugs that have not entered a clinical trial but
shows promising future in the treatment of EGFR mutant lung cancer. Furthermore, this article provides
concise information on relevant combinational or monotherapy clinical trials that have been
completed for various approaches.
Keywords: Lung cancer, epidermal growth factor receptor, epidermal growth factor receptor protein-tyrosine kinase, monoclonal
antibodies, ubiquitin, heat-shock protein, histone deacetylase.
Rights & PermissionsPrintExport